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Summary  An  early,  primary,  in  utero  cardiac  abnormality  may  prevent  normal  heart  deve-
lopment and  cause  irreversible  secondary  structural  changes.  The  idea  of  foetal  cardiac
intervention  stems  from  this  understanding  and  focuses  on  antenatal  intervention  targeting
the primary  abnormality  to  allow  normal  ﬂow  and  haemodynamics  and  thus  normal  heart  deve-
lopment.  Crucial  aspects  of  foetal  vascular  access,  varying  foetal  lie  and  structural  complexity
make it  very  hard  to  set  procedural  standards.  The  procedures  are  complex  and  are  associated
with signiﬁcant  maternal  and  foetal  morbidity  and  mortality.  The  high  risk-beneﬁt  ratio  clearly
explains  the  investigational  nature  of  such  therapies.  With  the  development  of  minimally  inva-
sive techniques  and  continued  animal  experiments,  foetal  interventional  therapy  may  see  a
low rate  of  morbidity  and  mortality,  improving  the  prognosis  of  newborns  with  congenital  heart
disease previously  considered  incurable.
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Résumé  Une  anomalie  cardiaque  précoce  intra-utérine  peut  empêcher  le  développement
normal du  cœur  et  causer  des  changements  structurels  secondaires  irréversibles.  L’idée
d’intervention  cardiaque  fœtale  prend  sa  source  dans  la  théorie  du  ﬂux  qui  indique  qu’une
cavité se  développe  au  prorata  du  sang  qui  la  traverse.  L’anomalie  précoce  est  ici  la  réduction
du ﬂux,  c’est-à-dire  l’obstacle  à  l’éjection.  Les  interventions  prénatales  ciblent  cette  anomalie
Abbreviations: AoS, aortic stenosis; CHD, congenital heart disease; HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right
eart syndrome; PAIVS, pulmonary atresia with intact ventricular septum; PS, pulmonary stenosis.
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primaire  pour  permettre  le  rétablissement  d’un  écoulement  et  d’une  hémodynamique  normale
et in  ﬁne  d’un  développement  normal  de  cœur.  Les  procédures  sont  complexes,  associées  à  une
morbidité signiﬁcative  et  à  une  mortalité  maternelles  et  fœtales.  Le  rapport  bénéﬁce/risque
actuel en  faveur  du  risque  explique  clairement  la  nature  expérimentale  de  telles  thérapies.  Les
résultats décevants  sont  expliqués  par  la  difﬁculté  d’accéder  au  mobile  fœtal  avec  du  matériel
non dédié  sur  des  malformations  d’anatomie  très  variables  dont  l’histoire  naturelle  est  mal
connue et  controversée.  Avec  le  développement  des  techniques  mini-invasives,  de  matériel
approprié  et  des  expérimentations  animales,  la  thérapie  interventionnelle  fœtale  pourrait  voir
ce rapport  augmenter  au  bénéﬁce  de  la  sécurité  avec  une  réduction  de  la  morbidité  et  de
la mortalité,  améliorant  le  pronostic  des  nouveau-nés  avec  la  maladie  cardiaque  congénitale
précédemment  considérée  incurable.
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Introduction
Percutaneous,  invasive,  per  utero,  foetal  therapies  have
been  developed  to  correct  and  prevent  progression  of
pathologies  diagnosed  in  utero  (such  as  spina  biﬁda,
diaphragmatic  hernia,  etc.).  Such  techniques  are,  how-
ever,  quite  challenging  to  apply  in  clinical  practice.  The
same  applies  to  the  art  and  science  of  foetal  cardiac  inter-
ventions  [1].  Congenital  heart  disease  (CHD)  is  the  most
common  inborn  defect,  occurring  in  about  19/1000  live
births  [2].  Advancements  in  imaging  technology  over  the
past  couple  of  decades,  with  the  development  of  high-
frequency,  high-resolution  probes,  have  made  accurate
diagnosis  of  most  CHDs  possible  during  foetal  life.  Colour
ﬂow  and  echocardiography-based  haemodynamic  foetal  car-
diac  assessment  in  pregnancy  allows  a  better  understanding
of  the  pathophysiology  of  even  complex  CHDs  [3].  Currently,
the  diagnosis  of  CHD  is  possible  only  after  the  end  of  the  ﬁrst
trimester  of  pregnancy  [4].  Such  scans  are  crucial  for  foe-
tuses  at  risk  of  CHD  due  to  a  strong  family  history,  maternal
exposure  to  toxic  drugs  or  chemicals,  speciﬁc  maternal  con-
ditions  and  nuchal  translucency  above  the  99th  percentile
[5].  The  diagnosis  of  CHD  at  an  early  stage  of  pregnancy
allows  enough  time  for  a  team  approach,  with  prenatal
and  genetic  counselling  by  the  expert  paediatric  cardiolo-
gist,  discussion  of  the  optimal  management  plan,  delivery
and  postnatal  care,  and  planning  for  future  pregnancies.
For  example,  once  diagnosed,  duct-dependent  CHD  should
be  referred  to  a  maternity  hospital  with  the  appropriate
neonatal  intensive  cardiac  support  to  reduce  perinatal  mor-
bidity  and  mortality  [6].  For  conditions  with  no  possibility
of  biventricular  repair,  the  expectant  parents  may  choose
between  postnatal  palliative  management  (such  as  the  Nor-
wood  procedure  for  hypoplastic  left  heart  syndrome  [HLHS])
or  for  interruption  of  pregnancy.  The  latter  option  is  cho-
sen  by  most  young  couples  in  our  country  nowadays.  Factors
like  these  and  our  insufﬁcient  knowledge  of  the  underlying
mechanisms  have  resulted  in  slow  progress  in  developing
effective  intrauterine  therapies  for  the  management  of
CHD.
In utero natural history and therapeutic
perspectives
The  impact  and  outcomes  of  invasive,  per  utero,  foetal
therapies  are  still  debated  and  there  are  differing  opinions
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mong  the  various  experts  [1].  It  is  hard  to  predict  the  nat-
ral  history  and  intrauterine  course  of  events.  There  is  a
chool  of  thought  that  the  natural  history  of  CHD  worsens
ver  time  and  that  it  is  best  to  perform  corrective  surgery
s  early  as  possible  (previously  performed  in  childhood  and
ow  carried  out  in  the  neonatal  period  or  infancy)  [7].  Others
elieve  that  the  outcome  of  CHD  is  deﬁnitively  deﬁned  from
n  anatomical  point  of  view  at  the  second  trimester  in  most
ases  and  that  foetal  intervention  would  not  alter  the  natu-
al  history,  except  in  case  of  foetal  hydrops.  The  ﬁrst  school
f  thought  is  based  on  the  ﬂow-driven  mechanistic  approach
hat  might  help  the  understanding  of  the  pathophysiology
f  some  severe  heart  diseases.  With  this  understanding,  it
s  believed  that  myocardial  chamber  growth  is  related  to
he  increasing  blood  ﬂow  into  the  cavities.  Thus,  with  in
tero  alteration  of  haemodynamics  and  blood  ﬂow  — and  the
esultant  morphological  and  functional  changes  —  CHD  may
rogress  and  may  be  worse  at  birth  than  originally  predicted.
Valvular  stenosis  may  result  in  poor  chamber  develop-
ent  by  reducing  the  blood  ﬂow.  Thus,  aortic  valve  stenosis
ay  be  the  root  cause  and  instigating  defect  leading  to
LHS,  small  or  virtual  left  ventricle,  mitral  atresia  and  aor-
ic  arch  abnormalities.  Once  the  crucial  phase  of  chamber
evelopment  is  reached,  it  becomes  irreversible,  despite
orrection  of  stenosis.  These  ﬁndings  have  inspired  the
dea  of  in  utero  catheter  intervention,  restoring  the  ﬂow
hrough  the  stenotic  valve  in  order  to  allow  the  develop-
ent  of  the  respective  chamber  and  thus  leave  the  option
or  a  biventricular  repair  after  birth.  Similar  interventions
ould  improve  the  global  prognosis  of  such  heart  malforma-
ions.  The  feasibility  of  an  interventional  approach  is  heavily
ependent  on  the  access  to  the  foetal  vascular  compart-
ent  and  on  acceptable  maternal  and  foetal  morbidity  and
ortality.
ccess to foetal vascular compartment
ordocentesis
ltrasound-guided  cordocentesis  was  ﬁrst  described  in
983  by  Daffos  et  al.  [8].  The  procedure  involves  per-
utaneous  access  to  the  foetal  vascular  compartment  to
raw  foetal  blood  for  cytological,  biochemical  and  cyto-
enetic  studies;  it  is  also  used  for  foetal  transfusion  in
ases  of  foetal  anaemia  due  to  maternofoetal  alloimmu-
ization.  Furthermore,  cordonal  access  allows  perfusion  of
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herapeutic  agents  to  the  foetus  for  sedation  analgesia  dur-
ng  technical  procedures  on  the  foetus,  such  as  setting  up  a
leuroamniotic  drain  in  the  management  of  hydrothorax  or
or  intracardiac  interventions.  The  risk  of  foetal  loss  related
o  the  cordocentesis  is  estimated  at  1—2%.  The  length  of  the
mbilical  cord  and  its  highly  tortuous  course  make  progres-
ion  with  a  guide  both  dangerous  (due  to  risk  of  perforation)
nd  technically  impracticable.
ardiocentesis
ercutaneous,  per  utero,  foetal,  transthoracic,  direct  ven-
ricular  access  was  proposed  as  an  alternative  to  cordonal
ccess  for  foetal  transfusion  in  cases  of  maternofoetal  rhe-
us  alloimmunization  when  cordonal  access  was  technically
mpossible  or  after  failure  [9].  Cardiocentesis  is  performed
ith  local  anaesthesia  to  the  maternal  skin  and  direct  needle
uncture  of  the  foetal  chest  wall  to  enter  the  foetal  left
entricle.
Besides  technical  problems  such  as  difﬁcult  access  with
arying  foetal  lie  and  catheter/balloon  fragmentation,  the
ate  of  foetal  loss  is  estimated  at  around  5.5—6.5%.  Cur-
ently,  cardiocentesis  is  seldom  or  not  used  in  the  indication
f  foetal  transfusion.  Its  current  indications  are  mainly  for
oetal  reduction  in  dichorionic  twin  pregnancies  if  one  of
he  foetuses  satisﬁes  the  indication  for  selective  termina-
ion  of  pregnancy,  such  as  aneuploidy.  This  technique  is  also
sed  for  therapeutic  acts  in  utero  on  foetuses  with  CHD.  It
equires  experience  in  percutaneous  puncture  under  ultra-
ound  guidance  as  well  as  in  foetal  echocardiography.  The
ccess  has  to  be  focused  on  the  area  to  be  treated  (e.g.
ransventricular  access  in  case  of  valvular  lesion).  The  right
entricle  is  usually  more  accessible  given  its  subparietal
ocation.  It  is  essential  to  precisely  locate  atrioventricular
alves,  valve  chordae  and  interventricular  septum  (contain-
ng  the  bundles  of  conduction)  in  order  to  avoid  injury  to
hese  structures  if  the  pregnancy  is  expected  to  continue.
oetoscopic access
ohl  et  al.  ﬁrst  described  foetoscopic  access  in  a  foetal
heep:  with  three  to  four  trocars  percutaneously  placed  in
he  uterus  and  videofoetoscopic  equipment,  they  achieved
 limited  thoracotomy  to  obtain  minimally  invasive,  direct,
oetal  cardiac  access  [10]. This  approach  was  tested  on  15
oetal  sheep  for  foetal  cardiac  pacing  or  antegrade  foetal
ardiac  catheterization.  The  technique  was  achieved  in  10
oetal  sheep  (ﬁve  failures  because  of  bleeding  or  technical
omplications);  eight  were  alive  at  the  end  of  the  procedure.
ix  ewes  continued  gestation;  three  non  premature  lambs
20%  of  cases)  were  born.  Foetal  death  occurred  in  seven
ases,  maternal  death  by  sepsis  in  two  cases  and  technical
omplications,  such  as  bleeding  of  the  puncture  site,  and
echnical  difﬁculty  in  identifying  the  subxyphoid  region  were
lso  noted.  Foetoscopic  access  has  some  advantages  com-
ared  with  maternal  hysterectomy  but  this  technique  is  not
one  in  humans  because  of  the  high  rate  of  complications.
To  provide  alternative  approaches  for  human  foetal  car-
iac  interventions,  the  same  team  described  transumbilical
oetal  cardiac  catheterization  in  sheep  by  minimally  invasive
oetoscopy,  guided  by  foetal  transoesophageal  echocardiog-
aphy  [11]. The  umbilical  cord  was  punctured  in  6/6  cases,
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ith the  possibility  of  anterograde  catheterization  into  the
oetal  heart.  However,  all  foetuses  died  secondary  to  dissec-
ion,  total  thrombosis  of  umbilical  vein  or  blood  loss  after
heath  dislodgment  or  removal.  Interestingly,  a  suture  at  the
heath  insertion  site  ensured  foetal  survival  for  1—2  weeks.
he  translation  of  cordonal  cardiac  catheterization  to  a
uman  foetus  seems  inconceivable  at  present;  its  interest
ies  in  the  simplicity  of  ultrasound  guidance  but  its  morbidity
nd  mortality  rates  in  animals  is  close  to  100%.
ranshepatic access
he  technical  deadlock  in  performing  transumbilical  foetal
ardiac  catheterization  led  to  the  suggestion  of  transhe-
atic  access  [12]. The  aim  was  to  reproduce  the  conditions
f  catheterization  using  Seldinger’s  technique  as  it  is  done
n  the  postnatal  period  and  to  improve  foetal  tolerance.
The  feasibility  of  anterograde,  echocardiography-guided,
ardiac  catheterization  through  a  transhepatic  approach  of
he  intra-abdominal  foetal  vessels  was  tested  on  ten  foetal
ambs.  Access  to  the  subdiaphragmatic  portion  of  the  infe-
ior  vena  cava  was  performed  by  ultrasound  guidance  via
 transhepatic  approach.  A  guide  was  placed  into  the  sub-
epatic  vein  and  cardiac  catheterization  was  performed
ccording  to  Seldinger’s  technique,  allowing  the  heart  cham-
ers  to  be  reached  in  all  cases,  with  atrial  or  ventricular
acing  in  six  foetuses  and  ballooning  of  the  pulmonary  valve
n  nine  cases  (Fig.  1).  Three  foetuses  died  after  the  proce-
ure  and  ﬁve  foetuses  were  born  at  term,  with  an  autopsy
howing  no  signiﬁcant  cardiac  or  peritoneal  injury.  The  sim-
licity  of  the  procedure,  with  its  shallow  learning  curve,
as  successfully  lowered  complication  rates  in  subsequent
tudies.  In  the  future,  this  method  could  become  an  alterna-
ive  to  percutaneous  transventricular  catheterization.  The
erioperative  bleeding  risk  could  be  reduced  by  peritoneal
eabsorption  of  red  blood  cells.  However,  variations  in  foetal
ositions  and  hepatic  vein  diameter  add  to  the  challenges;
he  latter  limits  this  method  to  the  second  part  of  pregnancy
hen  a  needle  can  be  safely  inserted.
ossible foetal cardiac interventions
n  theory,  foetal  cardiac  catheterization  can  be  planned  for
arious  types  of  aortic  and  pulmonary  valve  obstructions:
ulmonary  atresia  with  intact  ventricular  septum  (PAIVS)
perforation/ballooning);  HLHS  with  restrictive  atrial  sep-
al  defect  (enlargement  or  creation  of  an  atrial  septal
efect);  antenatal  closure  of  the  ductus  arteriosus  (stent
n  the  ductus  arteriosus);  rhythm  abnormalities  such  as
upraventricular  tachycardia  or  atrioventricular  block  (elec-
rophysiology  study,  ablation,  in  utero  pacing  lead);  total
berrant  pulmonary  venous  drainage  with  collector  vein
bstruction  (stent  in  the  collector  vein);  and  a few  other
xceptional  abnormalities  poorly  tolerated  before  birth,
uch  as  the  aorto-left  ventricular  tunnel  with  hydrops  (occlu-
ion  of  the  shunt).
Although  technically  feasible,  these  invasive  interven-
ions  still  have  to  be  performed  only  in  cases  with  a  low
isk-beneﬁt  ratio.  In  other  words,  the  risk  of  foetal  death
rom  the  cardiac  invasive  method  must  remain  lower  than
he  risk  of  spontaneous  foetal  death  (in  utero  or  early
n
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neonatal  death).  Thus,  the  intervention  must  provide  sur-
vival  of  the  foetus  until  the  end  of  pregnancy  if  there  is  risk
of  intrauterine  foetal  death,  along  with  improved  long-term
outcomes  by  modiﬁcation  of  cardiac  growth  and/or  cardiac
function.
With  the  proposed  mechanistic  theory,  each  heart  cham-
ber  grows  proportionately  to  its  blood  ﬂow  during  foetal
life  and  each  primitive  cardiac  defect  (such  as  blood  ﬂow
obstruction)  causes  secondary  heart  lesions.  So,  invasive
interventions  performed  during  the  foetal  development
period  will  aim  to  remove  this  primary  lesion  and  allow  a
better  and  theoretically  sufﬁcient  blood  ﬂow  through  the
heart  cavity,  to  ensure  cardiac  myocyte  proliferation  and
heart  cavity  growth.
The  three  acceptable  indications  where  foetal  interven-
tional  therapy  may  have  a  positive  impact  include:  balloon
aortic  valvuloplasty  for  the  prevention  of  HLHS;  balloon  pul-
monary  valvuloplasty  for  the  prevention  of  hypoplastic  right
heart  syndrome  (HRHS);  and  balloon  atrial  septostomy  to
improve  outcomes  in  patients  with  HLHS  and  restrictive  or
intact  interatrial  communication.
Prenatal balloon valvuloplasty in aortic
valve stenosis
Stringent  criteria  are  established  as  an  indication  for  this
procedure.  Only  midtrimester  foetuses  with  a  dominant
aortic  stenosis  (AoS)  lesion  and  a  potentially  salvageable
left  ventricle  must  be  considered  for  intervention.  The
left  ventricular  length  should  not  be  more  than  two  stan-
dard  deviations  below  the  mean  for  the  gestational  age,
with  severe  AoS  demonstrated  by  retrograde  ﬂow  in  the
ascending  aorta.  Kohl  et  al.  collected  data  on  foetal  car-
diac  intervention  worldwide  and  reported  that  among  14
foetuses,  eight  of  whom  had  isolated  aortic  valve  stenosis,
there  was  only  one  long-term  survivor  [10]. Kohl  and  Gem-
bruch  later  pointed  out  that  the  poor  outcomes  were  more
due  to  poor  results  of  postnatal  treatment  than  to  failure  of
the  intrauterine  interventions.
Tworezki  et  al.  ﬁrst  reported  a  series  of  20  cases  of  in
utero  balloon  valvuloplasty  for  severe  foetal  AoS  [13]. In
this  ﬁrst  series,  the  procedure  failed  technically  in  six  cases,
all  of  which  evolved  into  HLHS  (three  newborns,  one  medi-
cal  termination  of  pregnancy  and  two  foetal  deaths).  In  the
other  14  cases,  a  percutaneous  left  ventricular  approach  was
achieved,  with  a  limited  maternal  laparotomy  for  adequate
exposure  in  half  of  the  cases.  In  each  case,  a  balloon  was
inﬂated  through  the  aortic  valve  stenosis  .  Foetal  death  was
observed  in  two  cases  and  six  newborns  evolved  into  HLHS.
Finally,  the  procedure  was  technically  successful  in  three
cases,  with  a  functional  biventricular  heart  at  birth.  These
results  show  that  the  intervention  is  technically  feasible  in
three  quarters  of  cases,  but  raise  questions  about  the  identi-
ﬁcation  of  foetuses  who  would  beneﬁt  from  such  procedure
[14].  A  limited  maternal  laparotomy  could  be  performed  to
minimize  technical  constraints  but  it  carries  signiﬁcant  risks,
particularly  infections.  Patient  selection  is  difﬁcult  because
no  ultrasonographic  variable  has  yet  been  identiﬁed  to  accu-
rately  predict  the  effectiveness  of  the  technique  [15]. Only
some  criteria  have  been  described  as  predictors  of  the
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atural  course  to  HLHS  [16]. In  midgestation  foetuses  with
oS  and  normal  left  ventricular  length,  reversed  ﬂow  in  the
ransverse  aortic  arch  and  foramen  ovale,  monophasic  mitral
nﬂow  and  left  ventricular  dysfunction  are  predictive  of  pro-
ression  to  HLHS.  Another  series  published  in  2009  by  the
ame  team  included  70  foetuses  [17]. The  technical  success
ate  reached  74%  with  a  similar  technique.  Fifteen  children
22%)  were  born  with  a  functional  biventricular  heart.  The
tudy  of  biometric  and  biophysical  ultrasonographic  criteria
Doppler)  failed  to  reveal  reliable  variables  for  predicting
he  success  of  the  procedure  (predictive  positive  value  of
8%).
renatal balloon valvuloplasty in PAIVS
nd pulmonary stenosis
ased  on  the  ﬂow  theory  described  earlier  in  the  text,  PAIVS
nd  pulmonary  stenosis  (PS)  are  two  phenotypes  of  the  same
isease,  one  being  an  extension  of  the  other.  Some  stu-
ies  support  this  hypothesis,  showing  that  about  10%  of  PS
ill  evolve  into  pulmonary  atresia,  but  the  natural  course
f  these  right  heart  pathologies  remains  unclear.  Taking  into
onsideration  the  lack  of  knowledge  and  invasiveness  of  the
renatal  intervention  with  the  aim  of  decompressing  the
ight  ventricle,  the  unfavourable  forms  of  pulmonary  atresia
ith  HRHS  have  yet  to  be  deﬁned  [18].
Few  ultrasonographic  data  are  currently  available.  Based
n  retrospective  data  on  foetuses  with  pulmonary  atresia,
everal  authors  deﬁned  the  foetal  tricuspid  valve  size  as  a
redictor  of  postnatal  outcome  [19]. If  the  tricuspid  annu-
us  measured  less  than  three  standard  deviations  at  any
ime  of  pregnancy,  the  risk  of  progression  to  an  extreme
ypoplastic  right  ventricle  with  coronary  ﬁstula  was  impor-
ant.  In  addition,  a  progressively  narrowing  tricuspid  annulus
uring  pregnancy,  especially  when  very  small  in  early  ges-
ational  age,  is  another  important  predictor  of  hypoplastic
ight  ventricle.  The  antenatal  measure  was  quite  reliable
s  it  correlated  closely  with  the  postnatal  measure  [20].
n  summary,  foetuses  with  hypoplasia  of  the  tricuspid  valve
nnulus  seem  to  be  good  candidates  for  foetal  pulmonary
alve  dilation,  with  the  hope  of  improving  right  heart  growth
nd  thereby  the  prognosis  of  postnatal  management.
This  technique  has  been  applied  in  humans  in  several
mall  series,  with  fewer  than  30  foetuses  altogether  [18,21].
he  rate  of  technical  success  is  close  to  that  for  aortic  valve
ilation  (around  75—80%).  The  risk  for  the  foetus  (foetal
eath  and  preterm  birth)  is  similar  but  with  an  increased  risk
f  haemopericardium  due  to  the  use  of  a  thicker  needle  and
 bigger  balloon.  Most  cases  require  additional  endovascular
alvuloplasty  at  birth  to  achieve  effective  dilatation.  It  is  too
arly  to  say  whether  prenatal  dilatation  of  the  pulmonary
alve  changes  the  natural  history  of  this  heart  disease,  as
he  number  of  patients  treated  to  date  is  too  low.
LHS with intact or restrictive atrial
eptum
estrictive  atrial  septal  defect  during  foetal  life  leads  to
evere  haemodynamic  and  anatomical  lesions  (pulmonary
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Figure 1. Still echographic frames showing the various steps of pulmonary balloon dilatation after hepatic vein puncture: (A and B) the
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(atheter is seen entering and advancing in the inferior vena cava; 
he pulmonary valve; (D) the balloon is shown inﬂated in the pulmo
ein  wall  thickening)  because  of  the  chronic,  high-level  pres-
ure  in  the  left  atrium.  These  lesions  are  fatal  in  case  of
LHS,  as  demonstrated  by  the  high  neonatal  mortality  rate
around  85%)  despite  an  early  opening  of  the  atrial  septum
t  birth.
Several  teams  tried  to  remove  the  restriction  by  cre-
tion  of  an  atrial  septal  defect  as  soon  as  possible  during
regnancy,  to  prevent  the  development  of  lesions  encoun-
ered  after  birth.  The  Boston  experience,  with  a  cohort  of
m
a
b
igure 2. Still echographic frames showing the various steps of epicard
order of the heart; (B) the pacing lead has been anchored on the atrial
D) deceleration, after pacing has been turned on and off.hort-axis view showing the catheter across the right ventricle and
 valve area.
1  foetuses,  reported  poor  results:  an  atrial  septal  defect
as  created  in  19  foetuses  with  a restrictive  atrial  septal
efect  but  postnatal  mortality  remained  higher  (58%)  than
n  cases  of  HLHS  without  restriction,  given  that  for  technical
easons  the  procedure  was  feasible  only  at  the  beginning  of
he  third  quarter  of  the  pregnancy  [22]. The  rate  of  early
ortality  by  haemopericardium  reaches  around  10%,  as  for
ortic  valvuloplasty.  In  the  future,  with  technical  advances,
etter  results  could  be  expected  with  an  earlier  and  more
ial stimulation: (A) the needle is shown in contact with the external
 wall; M-mode still frames showing heart rate (C) acceleration and
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[Foetal  cardiac  interventions  
aggressive  intervention,  such  as  stenting,  rather  than  single
dilation  to  prevent  the  risk  of  restenosis.
The way forward
There  are  several  aspects  that  need  signiﬁcant  work  to
improve  the  technique  and  outcomes  of  foetal  interven-
tions.  Despite  the  timing  of  foetal  valvuloplasty  during  the
second  quarter  of  pregnancy,  the  results  are  generally  disap-
pointing;  about  70%  of  foetuses  with  successful  valvuloplasty
evolve  to  postnatal  univentricular-type  management.  Sev-
eral  points  need  to  be  addressed;  better  understanding  of
the  in  utero  natural  history  of  CHD  for  better  selection  of
patients;  improvement  of  the  interventional  armamenta-
rium  and  evolution  of  techniques  to  facilitate  intervention
earlier  in  the  natural  course  for  favourable  haemody-
namic  and  structural  outcomes;  and  evaluation  of  long-term
outcomes  of  foetal  cardiac  interventions  (e.g.  compare
evolution  of  successfully  dilated  and  biventricular-repaired
patients  with  patients  receiving  palliative  management  for
an  equivalent  heart  disease).  With  better  imaging  tech-
niques  and  a  better  understanding  of  in  utero  CHD,  the
number  of  foetuses  requiring  such  interventional  procedures
may  increase.  Foetal  cardiac  catheterization  through  a  tran-
shepatic  access  is  being  well  studied  in  animals  and  could
potentially  become  a  new  interventional  approach  in  human
foetuses.
Work  on  foetal  epicardial  pacing  is  also  ongoing;  with
a  specially  designed  lead,  transcutaneous,  echo-guided,
foetal  acute  pacing  is  feasible  in  foetal  sheep  (Fig.  2)  [23].
Additional  reﬁnement  of  both  the  equipment  and  the  oper-
ative  technique  is  required  before  considering  permanent
pacing  in  the  human  foetuses.  This  technique  may  prove  to
be  highly  valuable  in  cases  of  hydrops  foetalis  secondary  to
either  congenital  complete  heart  block  or  due  to  incessant
supraventricular  tachycardia  where  there  may  be  the  option
to  pace-terminate.  Cordonal  puncture  for  the  administra-
tion  of  antiarrhythmic  agents  can  also  be  an  option.  In  brief,
interventional  foetal  cardiac  catheterization  shows  promise
for  the  treatment  of  the  human  foetus.
Conclusion
Understanding  the  development  and  progression  of  struc-
tural  abnormalities  in  utero  is  quite  challenging.  An  early,
primary,  in  utero  abnormality  may  prevent  normal  heart
development  and  cause  irreversible  secondary  structural
changes.  The  idea  of  foetal  cardiac  intervention  stems  from
this  understanding  and  focuses  on  antenatal  intervention
to  target  the  primary  abnormality,  to  allow  normal  ﬂow
and  thus  normal  heart  development.  Access  to  the  foetal
heart,  however,  is  the  most  crucial  aspect  of  this  ambitious
project.  The  tremendous  variations  in  the  amount  of  amni-
otic  ﬂuid,  foetal  lie  and  structural  complexity  make  it  very
hard  to  set  standards.  Various  techniques  have  been  devel-
oped  in  animals  to  facilitate  approaching  the  foetal  vascular
compartment.  Currently,  the  percutaneous  transventricular
approach  is  most  commonly  used  for  interventional  foetal
cardiac  catheterization.  Technical  improvement  and  experi-
ence  of  different  teams  show  varying  results.  These  invasive
[371
rocedures  are  designed  for  foetuses  with  CHD  whose  post-
atal  management  is  deemed  palliative.  In France,  the
evelopment  of  these  procedures  is  poor,  as  many  young
ouples  opt  for  medical  termination  of  the  pregnancy  with
uch  pathologies.  Moreover,  these  procedures  are  complex
nd  associated  with  signiﬁcant  maternal  and  foetal  morbi-
ity,  which  clearly  explains  the  high  risk-beneﬁt  ratio  and
he  investigational  nature  of  such  therapies.  With  the  devel-
pment  of  minimally  invasive  techniques  and  continued
nimal  experiments,  foetal  interventional  therapy  may  see
 low  rate  of  morbidity  and  mortality,  improving  the  progno-
is  of  newborns  with  CHD,  who  were  previously  considered
ncurable.
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